How much funding has Ouro Medicines raised?

Ouro Medicines has raised $120.0M in total funding, most recently a Series A round.

Who are Ouro Medicines's investors?

Ouro Medicines's investors include New Enterprise Associates, Shiv Chaudhary, TPG Life Sciences Innovation, GSK, Monograph Capital, Boyu Capital.

When was Ouro Medicines founded?

Ouro Medicines was founded in 2025.

Where is Ouro Medicines headquartered?

Ouro Medicines is headquartered in USA, California, United States.

What industry is Ouro Medicines in?

Ouro Medicines operates in Biotech, Immunology, Therapeutics, Drug Discovery, Healthcare.

How many employees does Ouro Medicines have?

Ouro Medicines has 11-50 employees.

Ouro Medicines

Defining the future of treatment for people with immune-mediated diseases

USA, United States · Founded 2025 · $120.0M raised

Immunology

Headquarters: USA, California
Employees: 11–50
Founded: 2025
Business Model: B2B

Website: ouromedicines.com
Total Funding: $120.0M
Last Round: $120.0M Series AJan 2025
Rounds: 1

About

Ouro Medicines is a clinical-stage biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases. Its lead program, OM336 (gamgertamig), is a BCMAxCD3 T cell engager in a basket study targeting multiple autoimmune conditions, and has received FDA Fast Track and Orphan Drug designations. In March 2026, Gilead Sciences announced an agreement to acquire Ouro for approximately $2.18 billion.

Summary

Ouro Medicines is a Biotech company based in USA, United States, founded in 2025. It has raised $120.0M in total across 1 round, most recently a $120.0M Series A round in Jan 2025. Investors include New Enterprise Associates, Shiv Chaudhary and TPG Life Sciences Innovation.